Expanded Access Part 1: Introduction

Expanded Access Part 2: How to Submit a Single Patient IND

Expanded Access Part 4: How to Complete Form FDA 3926 for Follow-Up Submissions

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

Roundtable on PMTA Submissions for ENDS Products

FDA Direct: Combating Rare Diseases at the FDA

Vaccines and Related Biological Products Advisory Committee Meeting

FDA Celebrates 120 Years

FDA Expert Panel on Food Allergies

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA’s Rare Disease Day 2026 – An Event for Patients

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

January 22, 2026: Tobacco Products Scientific Advisory Committee Meeting

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

FDA-USP-AAM | D1S4 – Q&A Discussion Panel

Adeno-Associated Virus-Mediated Gene Therapy - Advances, Immune Challenges, and Research Innovations

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease